Higher co-payments increase chance of early discontinuation, inadequate use of breast cancer therapy
SAN ANTONIO — A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early-stage breast cancer.
Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, presented detailed study results at the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, ...
